Studying microbial resistance to drugs and developing new strategies to combat infections: Review

Authors

  • Mazin Abdulridha Ateyah College of Pharmacy, Uruk University, Baghdad, Iraq.

Abstract Anti- microbial resistance is a public health concern worldwide and requires a new strategy to combat these resistant microorganisms. This review seeks to discuss important approaches to combating AMR. This review demonstrated that enzyme inhibitors are advertised for their capacity to counteract the bacterial enzymes that make antibiotic-resistant. Lantibiotics and bacteriocins are two classes of naturally occurring antimicrobial peptides that can be used as therapeutic agents because they attack the cell wall and/or cell membrane of bacteria. Another avenue is with AMPs that are characterized by a broad-spectrum activity and can target most of the resistant bacteria. Nanoparticle-based strategies present a modern approach to increasing efficacy, stability, and targeted delivery of antimicrobial agents coupled with decreased toxicity. Monoclonal antibodies are more specific drugs as they act against bacterial antigens and prevent their toxicity. The bacteriophage therapy that involves utilizing viruses that target and destroy bacteria presents a targeted treatment method against drug-resistant strains and can also be personalized for specific infection types. This review further emphasizes the need to sustain the research efforts, international cooperation, and funding of these novel therapies in the face of growing concern about AMR. Therefore, it is crucial to continue using the multifaceted methods introduced to find the ways to improve the treatment and the future of combating infections.

Keywords:

Antibiotic resistance, Lantibiotics, Bacteriocins, Monoclonal Antibodies, Antimicrobial Peptides, Antimicrobial PeptidesAdverse effects, Alternative therapies

[1] Shatalin, K., Nuthanakanti, A., Kaushik, A., Shishov, D., Peselis, A., Shamovsky, I., ... & Nudler, E. (2021). Inhibitors of bacterial H2S biogenesis targeting antibiotic resistance and tolerance. Science, 372(6547), 1169-1175.‏

[2] El-Halfawy, O. M., Czarny, T. L., Flannagan, R. S., Day, J., Bozelli, J. C., Kuiack, R. C., ... & Brown, E. D. (2020). Discovery of an antivirulence compound that reverses β-lactam resistance in MRSA. Nature chemical biology, 16(2), 143-149.

[3] Lorenz, A., Pawar, V., Häussler, S., & Weiss, S. (2016). Insights into host–pathogen interactions from state‐of‐the‐art animal models of respiratory Pseudomonas aeruginosa infections. FEBS letters, 590(21), 3941-3959.

[4] ‏An, S. (2022). Developing Fusion Bacteriocins for Eradicating Pseudomonas Aeruginosa Biofilms (Master's thesis, Illinois Institute of Technology).

[5] ‏Antonova, N. P., Vasina, D. V., Lendel, A. M., Usachev, E. V., Makarov, V. V., Gintsburg, A. L., ... & Gushchin, V. A. (2019). Broad bactericidal activity of the Myoviridae bacteriophage lysins LysAm24, LysECD7, and LysSi3 against Gram-negative ESKAPE pathogens. Viruses, 11(3), 284.

[6] ‏Grygorcewicz, B., Roszak, M., Golec, P., Śleboda-Taront, D., Łubowska, N., Górska, M., ... & Dołęgowska, B. (2020). Antibiotics act with vB_AbaP_AGC01 phage against Acinetobacter baumannii in human heat-inactivated plasma blood and Galleria mellonella models. International Journal of Molecular Sciences, 21(12), 4390.

[7] ‏Jun, S. Y., Jang, I. J., Yoon, S., Jang, K., Yu, K. S., Cho, J. Y., ... & Kang, S. H. (2017). Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrobial agents and chemotherapy, 61(6), 10-1128.

[8] ‏Totté, J. E., van Doorn, M. B., & Pasmans, S. G. (2017). Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin Staphefekt SA. 100: a report of 3 cases. Case reports in dermatology, 9(2), 19-25.

[9] ‏Schuch, R., Cassino, C., & Vila-Farres, X. (2022). Direct lytic agents: novel, rapidly acting potential antimicrobial treatment modalities for systemic use in the era of rising antibiotic resistance. Frontiers in Microbiology, 13, 841905.

[10] ‏Fowler, V. G., Das, A. F., Lipka-Diamond, J., Schuch, R., Pomerantz, R., Jáuregui-Peredo, L., ... & Cassino, C. (2020). Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. The Journal of clinical investigation, 130(7), 3750-3760.

[11] ‏Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y. A., Resch, G., ... & Gabard, J. (2019). Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. The Lancet Infectious Diseases, 19(1), 35-45.

[12] ‏Tan, X., Chen, H., Zhang, M., Zhao, Y., Jiang, Y., Liu, X., ... & Ma, Y. (2021). Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Frontiers in cellular and infection microbiology, 11, 631585.

[13] ‏Shang, D., Han, X., Du, W., Kou, Z., & Jiang, F. (2021). Trp-containing antibacterial peptides impair quorum sensing and biofilm development in multidrug-resistant Pseudomonas aeruginosa and exhibit synergistic effects with antibiotics. Frontiers in microbiology, 12, 611009.‏

[14] Elsalem, L., Khasawneh, A., & Al Sheboul, S. (2022). WLBU2 antimicrobial peptide as a potential therapeutic for treatment of resistant bacterial infections. Turkish Journal of Pharmaceutical Sciences, 19(1), 110.‏

[15] Elsalem, L., Al Sheboul, S., & Khasawneh, A. (2021). Synergism between WLBU2 peptide and antibiotics against methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Enterobacter cloacae. Journal of Applied Biomedicine, 19(1).

[16] Zurawski, D. V., & McLendon, M. K. (2020). Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics, 9(4), 155.‏

[17] OIE–World Organization for Animal Health. (2015). OIE list of antimicrobial agents of veterinary importance.

[18] Patel, J., Harant, A., Fernandes, G., Mwamelo, A. J., Hein, W., Dekker, D., & Sridhar, D. (2023). Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries. The Lancet Infectious Diseases, 23(6), 706-718.

[19] ‏Nabadda, S., Kakooza, F., Kiggundu, R., Walwema, R., Bazira, J., Mayito, J., ... & Mwebasa, H. (2021). Implementation of the World Health Organization global antimicrobial resistance surveillance system in Uganda, 2015-2020: mixed-methods study using national surveillance data. JMIR Public Health and Surveillance, 7(10), e29954.

[20] ‏Brüssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. Microbial Biotechnology, 17(7), e14510.

[21] ‏Lerminiaux, N. A., & Cameron, A. D. (2019). Horizontal transfer of antibiotic resistance genes in clinical environments. Canadian journal of microbiology, 65(1), 34-44.

[22] ‏Ahmed, S. K., Hussein, S., Qurbani, K., Ibrahim, R. H., Fareeq, A., Mahmood, K. A., & Mohamed, M. G. (2024). Antimicrobial resistance: impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health, 2, 100081.

[23] ‏Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. (2023, July). Antimicrobial resistance: a growing serious threat for global public health. In Healthcare (Vol. 11, No. 13, p. 1946). MDPI.

[24] Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., ... & Haque, M. (2020). Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Frontiers in Public Health, 8, 535668.

[25] ‏Carvalho, I., Silva, N., Carrola, J., Silva, V., Currie, C., Igrejas, G., & Poeta, P. (2019). Antibiotic resistance: Immunity‐acquired resistance: Evolution of antimicrobial resistance among extended‐spectrum β‐lactamases and carbapenemases in Klebsiella pneumoniae and Escherichia coli. Antibiotic drug resistance, 239-259.

[26] ‏Pateiro, M., Munekata, P. E., Sant'Ana, A. S., Domínguez, R., Rodríguez-Lázaro, D., & Lorenzo, J. M. (2021). Application of essential oils as antimicrobial agents against spoilage and pathogenic microorganisms in meat products. International Journal of Food Microbiology, 337, 108966.

[27] ‏Christaki, E., Marcou, M., & Tofarides, A. (2020). Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. Journal of molecular evolution, 88(1), 26-40.

[28] ‏Zhang, F., & Cheng, W. (2022). The mechanism of bacterial resistance and potential bacteriostatic strategies. Antibiotics, 11(9), 1215.

[29] ‏Reygaert, W. C. (2018). An overview of the antimicrobial resistance mechanisms of bacteria. AIMS microbiology, 4(3), 482.

[30] ‏Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., ... & Jose, R. A. M. (2022). Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics. Antibiotics 2022; 11: 200. Selected recent Ukrainian OA Papers, 23.

[31] ‏Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare 2023, 11, 1946.

[32] ‏Moo, C. L., Yang, S. K., Yusoff, K., Ajat, M., Thomas, W., Abushelaibi, A., ... & Lai, K. S. (2020). Mechanisms of antimicrobial resistance (AMR) and alternative approaches to overcome AMR. Current drug discovery technologies, 17(4), 430-447.

[33] ‏Coates, A. R., Hu, Y., Holt, J., & Yeh, P. (2020). Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert review of Anti-infective therapy, 18(1), 5-15.

[34] Baindara, P., & Mandal, S. M. (2019). Antimicrobial peptides and vaccine development to control multi-drug resistant bacteria. Protein and Peptide Letters, 26(5), 324-331.‏

[35] Lopes, B. S., Hanafiah, A., Nachimuthu, R., Muthupandian, S., Md Nesran, Z. N., & Patil, S. (2022). The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance. Molecules, 27(9), 2995.‏

[36] Soltani, S., Hammami, R., Cotter, P. D., Rebuffat, S., Said, L. B., Gaudreau, H., ... & Fliss, I. (2021). Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. FEMS microbiology reviews, 45(1), fuaa039.‏

[37] Walsh, L., Johnson, C. N., Hill, C., & Ross, R. P. (2021). Efficacy of phage-and bacteriocin-based therapies in combatting nosocomial MRSA infections. Frontiers in molecular biosciences, 8, 654038.‏

[38] Majumder, M. A. A., Rahman, S., Cohall, D., Bharatha, A., Singh, K., Haque, M., & Gittens-St Hilaire, M. (2020). Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infection and drug resistance, 4713-4738.

[39] ‏Shriram, V., Khare, T., Bhagwat, R., Shukla, R., & Kumar, V. (2018). Inhibiting bacterial drug efflux pumps via phyto-therapeutics to combat threatening antimicrobial resistance. Frontiers in microbiology, 9, 2990.

[40] ‏Chen, X., Wong, C. H., & Ma, C. (2019). Targeting the bacterial transglycosylase: antibiotic development from a structural perspective. ACS Infectious Diseases, 5(9), 1493-1504.

[41] ‏Tehrani, K. H., & Martin, N. I. (2018). β-lactam/β-lactamase inhibitor combinations: an update. Medchemcomm, 9(9), 1439-1456.

[42] ‏Mathur, H., Field, D., Rea, M. C., Cotter, P. D., Hill, C., & Ross, R. P. (2018). Fighting biofilms with lantibiotics and other groups of bacteriocins. npj Biofilms and Microbiomes, 4(1), 9.

[43] ‏Fernandes, A., Yadav, P., Nalawade, O., Joshi, S., & Jobby, R. (2023). Properties, classification and applications of lantibiotics from Gram-positive bacteria. In Lantibiotics as Alternative Therapeutics (pp. 411-425). Academic Press.

[44] ‏Al-Omari, A. W., Matter, I. R., & Almola, A. H. (2022). An overview of Bacteriocins. Samarra Journal of Pure and Applied Science, 4(2), 58-72.

[45] Nataraj, B. H., Naithani, H., Nagpal, R., & Behare, P. V. (2022). Bacteriocins and antimicrobial peptides as an alternative to antibiotics. In Advances in Dairy Microbial Products (pp. 327-346). Woodhead Publishing.

[46] ‏Ansari, A., Zohra, R. R., Tarar, O. M., Qader, S. A. U., & Aman, A. (2018). Screening, purification and characterization of thermostable, protease resistant Bacteriocin active against methicillin resistant Staphylococcus aureus (MRSA). BMC microbiology, 18, 1-10.

[47] Sivam, V., Rangasamy, A., & Dara, P. K. (2023). Nanoparticle approach to control AMR. In Handbook on Antimicrobial Resistance: Current Status, Trends in Detection and Mitigation Measures (pp. 925-946). Singapore: Springer Nature Singapore.

[48] ‏Al-Awsi, G. R. L., Alameri, A. A., Al-Dhalimy, A. M. B., Gabr, G. A., & Kianfar, E. (2023). Application of nano-antibiotics in the diagnosis and treatment of infectious diseases. Brazilian Journal of Biology, 84, e264946.

[49] ‏Mishra, A., Pradhan, D., Halder, J., Biswasroy, P., Rai, V. K., Dubey, D., ... & Rath, G. (2022). Metal nanoparticles against multi-drug-resistance bacteria. Journal of inorganic biochemistry, 237, 111938.

[50] ‏Sánchez-López, E., Gomes, D., Esteruelas, G., Bonilla, L., Lopez-Machado, A. L., Galindo, R., ... & Souto, E. B. (2020). Metal-based nanoparticles as antimicrobial agents: an overview. Nanomaterials, 10(2), 292.

[51] ‏More, P. R., Pandit, S., Filippis, A. D., Franci, G., Mijakovic, I., & Galdiero, M. (2023). Silver nanoparticles: bactericidal and mechanistic approach against drug resistant pathogens. Microorganisms, 11(2), 369.

[52] ‏Li, M., Liu, Y., Gong, Y., Yan, X., Wang, L., Zheng, W., ... & Zhao, Y. (2023). Recent advances in nanoantibiotics against multidrug-resistant bacteria. Nanoscale Advances.

[53] ‏Panico, S., Capolla, S., Bozzer, S., Toffoli, G., Dal Bo, M., & Macor, P. (2022). Biological features of nanoparticles: protein corona formation and interaction with the immune system. Pharmaceutics, 14(12), 2605.

[54] ‏Poon, W. (2020). Defining Delivery Pathways of Nanoparticles. University of Toronto (Canada(

[55] ‏Castelli, M. S., McGonigle, P., & Hornby, P. J. (2019). The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology research & perspectives, 7(6), e00535.

[56] ‏McConnell, M. J. (2019). Where are we with monoclonal antibodies for multidrug-resistant infections?. Drug Discovery Today, 24(5), 1132-1138.

[57] ‏Reuter, M., & Kruger, D. H. (2020). Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections. Virus Genes, 56(2), 136-149.

[58] Düzgüneş, N., Sessevmez, M., & Yildirim, M. (2021). Bacteriophage therapy of bacterial infections: the rediscovered frontier. Pharmaceuticals, 14(1), 34.

[59] ‏North, O. I., & Brown, E. D. (2021). Phage–antibiotic combinations: a promising approach to constrain resistance evolution in bacteria. Annals of the New York Academy of Sciences, 1496(1), 23-34.

[60] ‏Oechslin, F. (2018). Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses, 10(7), 351.

Studying microbial resistance to drugs and developing new strategies to combat infections: Review. (2025). Journal Port Science Research, 8(1), 89-100. https://doi.org/10.36371/port.2025.1.15

License

Copyright (c) 2025 Journal Port Science Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

Studying microbial resistance to drugs and developing new strategies to combat infections: Review. (2025). Journal Port Science Research, 8(1), 89-100. https://doi.org/10.36371/port.2025.1.15